Learn more about the role of topical therapy in psoriasis management, including:
- Patient perspectives with Professor Peter van de Kerkhof
- Real-world experience of long-term topical treatment with Dr Andreas Pinter
- The psychosocial impact of psoriasis and importance of improving treatment adherence with Professor Anthony Bewley
This content is from the Almirall-sponsored symposium ‘Tailoring topical psoriasis treatments to patients’ needs and expectations’, presented at the EADV Virtual Congress 2021. This symposium was created in collaboration with the expert faculty and is intended for health care professionals only.
Watch the full Almirall-sponsored symposium ‘Tailoring topical psoriasis treatments to patients’ needs and expectations’ below, for expert insights into the optimisation of topical treatment in people living with psoriasis.
Short of time? Watch bitesize symposium highlights below.
For various reasons, many patients fail to adhere to topical treatment regimens for their psoriasis. These videos explore the role of topical therapy in psoriasis management and how these therapies can be tailored to meet the needs and expectations of patients. This includes an overview of current management strategies and the development of new topical formulations, as well as real-world evidence on the use of topical treatments, and insights into the dermatologist’s role in the prevention and management of psychological comorbidities in psoriasis.
Meet the Experts
Professor Peter van de Kerkhof
Senior Professor of Radboud University in Nijmegen, the Netherlands. Professor Van de Kerkhof is also Chief Medical Officer of the International Psoriasis Council.
Dr Andreas Pinter
Medical Director of Clinical Research and Senior Physician at the Department of Dermatology, University Hospital of Frankfurt am Main.
Professor Anthony Bewley
Consultant Dermatologist at Whipps Cross and Barts. Professor Bewley is also an Honorary Senior Lecturer at Queen Mary Medical School, University of London.
The Psoriasis Management, Psoriasis Treatment and Psoriasis Guidelines content has been developed by EPG Health for Medthority. This content has been developed independently of the sponsor Almirall S.A, who have had no editorial input into the content. EPG Health received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.
The Industry-sponsored symposia content has been developed by EPG Health for Medthority in collaboration with the sponsor Almirall S.A., utilising content from their Almirall funded symposium at EADV 2021.